1. What are the most significant findings regarding the safety and efficacy of psychedelics in treating mental health conditions?

The most significant finding is that psychedelic-assisted therapies may offer a fundamentally different approach to treating certain mental health conditions, particularly where conventional treatments have not been effective. Research into psilocybin, for example, has shown promising results in treatment-resistant depression, with some patients experiencing prolonged periods of remission when the substance is used alongside psychotherapy.

There is also growing evidence that psychedelics may temporarily disrupt rigid patterns of brain activity and create a period of increased cognitive flexibility and neuroplasticity. This may allow patients, when supported by psychotherapy, to develop healthier patterns of thinking and emotional processing.

However, the evidence should not be overstated. None of these treatments are cures, although the word “cure” has certainly been used in the past few years in psychiatry, with reference to MDMA for Post-Traumatic Stress Disorder (PTSD). Successful treatment depends heavily on appropriate patient selection, screening, preparation, clinical supervision and integration. Of note is that clinicians need to be up-skilled in the psychopharmacology of these potential medicines, as there may be important interactions with psychiatric medications and hence potential risks for particular patients. The emerging evidence is encouraging but rigorous research and responsible clinical practice remain essential.

2. How do you envision the future of psychedelic therapy integrating into conventional psychiatric practices?

I see psychedelic therapy potentially becoming another tool within the psychiatrist’s treatment framework rather than a replacement for conventional psychiatry.

The important distinction is that psychedelic-assisted therapy is not simply about giving someone a substance. The therapeutic process must involve careful screening and preparation beforehand, and a skilled, ethically sound, supported medicine session (usually multiple) afterwards. The Multidisciplinary Association for Psychedelic Science (MAPS) MDMA-assisted therapy for PTSD, for example, illustrates how structured and intensive that model can be.

As the evidence develops, we may see psychedelic treatments being considered alongside existing medications and psychotherapies, depending on the patient’s condition and individual circumstances. Ketamine already provides an example of how a non-traditional treatment can become part of psychiatric practice, although its potential for dependence and the need for maintenance treatment must also be taken into consideration.

Ultimately, integration should be evidence-led and patient-centred, rather than driven by the effusive excitement we have observed surrounding psychedelics.

3. Can you discuss any potential ethical concerns surrounding the use of psychedelics in mental healthcare?

There are several important ethical considerations. First is patient safety and appropriate screening. Psychedelic experiences can be extremely powerful, hence clinicians need to understand who may be suitable for treatment, who may be at increased risk and what medication interactions or contraindications need to be considered.

There is also an ethical responsibility not to present psychedelics as a cure for all psychiatric ailments — the so-called “silver bullet”. We need to guard against what Michael Pollan named as “psychedelic narcissism” — the belief that these substances are guaranteed cures. Patients deserve accurate information about both the potential benefits and the limitations of the evidence.

Another consideration is the therapeutic relationship and the vulnerability of patients during altered states of consciousness. This makes it of utmost importance that professional boundaries are agreed upon and adhered to, adequate supervision is provided, and informed consent and appropriate vigilance are applied around ethical conduct.

Finally, there is the question of equitable access. If these treatments prove effective, we need to consider who will actually be able to access them, particularly within South Africa’s unequal healthcare system. Innovation in mental healthcare should not simply create another treatment available only to those who can afford it. It is our role as healthcare providers to target or modify interventions in South Africa, to create opportunities for all socioeconomic groups.

4. What role do you believe education and training will play in preparing mental health professionals for the use of psychedelics?

Education and training will be absolutely fundamental. Mental health professionals need to be upskilled not only in the psychopharmacology and neuroscience of psychedelics, but also the psychological experience, specifically the nature of the non-ordinary state of consciousness (NOSC) they produce, and how that experience can be incorporated into therapy.

Training should include patient screening, contraindications and medication interactions, preparation, psychological support during the psychedelic experience, and integration afterwards. Clinicians also need to understand the limitations of the evidence and be able to communicate those limitations honestly to patients.

This is particularly important because psychedelic therapy requires a different level of therapeutic engagement from simply prescribing a conventional medication. The clinician needs to be able to create a safe environment in which patients can process what emerges during the experience.

As the field develops, appropriate professional standards, multidisciplinary training and evidence-based clinical protocols will be important to ensure that enthusiasm for these treatments does not compromise patient safety.

5. How can we address the stigma associated with psychedelic treatments to encourage more open discussions in the medical community?

The best way to address stigma is through open, evidence-based discussion. Psychedelics have historically been associated with recreational drug use, which presents conceptual challenges around their therapeutic potential. But the answer is not to dismiss those concerns; it is to examine the evidence carefully.

We need to distinguish between recreational use and a medically supervised therapeutic intervention. In clinical research, the substance forms part of a much broader treatment process involving screening, preparation, supervision and integration.

At the same time, we should avoid falling into the trap of adopting a binary approach, as we have seen, for example, with Western psychiatric medicine and complementary medicine. People tend to switch from one to another. Psychedelics should neither be dismissed because of their history nor promoted as miracle cures. The medical community needs to be able to say: these treatments are promising, some evidence is encouraging, there are genuine risks and unanswered questions, and we need more rigorous research.

Finally, psychedelics indubitably provide exciting potential for the continued elucidation of neurobiological actions in the brain and their therapeutic potential, but once again it needs to be emphasised that they are bound to be incorporated into what hopefully will become an ever-growing pharmacopoeia with which we can approach mental illness.

Find out more at www.firstlight.healthcare